Skip to Main Content

Author Details

Ingrid Hedenfalk
Lund University and Skane University Hospital
1997
73
28
PMIDPaper TitleJournal TitlePublished Year
36733702A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer.Comput Struct Biotechnol J2023
37404831Breast cancer associated CD169<sup>+</sup> macrophages possess broad immunosuppressive functions but enhance antibody secretion by activated B cells.Front Immunol2023
36831605CD169<sup>+</sup> Macrophages in Primary Breast Tumors Associate with Tertiary Lymphoid Structures, T<sub>regs</sub> and a Worse Prognosis for Patients with Advanced Breast Cancer.Cancers (Basel)2023
35974007RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer.NPJ Breast Cancer2022
36010992How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer.Cancers (Basel)2022
32785646Common Susceptibility Loci for Male Breast Cancer.J Natl Cancer Inst2021
33602289Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.Breast Cancer Res2021
33602273Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.Breast Cancer Res2021
33714010Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.ESMO Open2021
33662273Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer.Mol Cell2021
34069138MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer.Genes (Basel)2021
34036235Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.JCO Precis Oncol2021
34312396Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.NPJ Breast Cancer2021
33445465Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.Cancers (Basel)2021
32905537Transcriptomic and functional pathway features were associated with survival after pathological complete response to neoadjuvant chemotherapy in breast cancer.Am J Cancer Res2020
31980961PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.Virchows Arch2020
33088426Simvastatin is a potential candidate drug in ovarian clear cell carcinomas.Oncotarget2020
33032823High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.Gynecol Oncol2020
33075095A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.PLoS One2020
33235906SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery.Mol Cell Oncol2020
30692208Afadin cooperates with Claudin-2 to promote breast cancer metastasis.Genes Dev2019
31664085Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method.Sci Rep2019
31857852Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.Oncotarget2019
31174567Extracellular lipid loading augments hypoxic paracrine signaling and promotes glioma angiogenesis and macrophage infiltration.J Exp Clin Cancer Res2019
29092024Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.Ann Oncol2018
30206250Ghrelin expression is associated with a favorable outcome in male breast cancer.Sci Rep2018
30228933Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.Oncoimmunology2018
28481779Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.Int J Gynecol Pathol2018
29396493Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.Nat Commun2018
28940389Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.Int J Cancer2018
27986751A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer.Clin Cancer Res2017
29029636Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.Breast Cancer Res2017
29136509An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.Cancer Cell2017
28611940Involvement of Chromatin Remodeling Genes and the Rho GTPases <i>RhoB</i> and <i>CDC42</i> in Ovarian Clear Cell Carcinoma.Front Oncol2017
26276891Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.Clin Cancer Res2016
25990542Genome methylation patterns in male breast cancer - Identification of an epitype with hypermethylation of polycomb target genes.Mol Oncol2015
26375671Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.Oncotarget2015
26319607Clinical and molecular complexity of breast cancer metastases.Semin Cancer Biol2015
26500033Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.Transl Oncol2015
25840970Global Transcriptional Changes Following Statin Treatment in Breast Cancer.Clin Cancer Res2015
25925673Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.J Transl Med2015
24287398Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.Mol Oncol2014
25226589Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.PLoS One2014
24842109Molecular profiling of male breast cancer - lost in translation?Int J Biochem Cell Biol2014
22928693Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact.Acta Oncol2013
24194916The landscape of candidate driver genes differs between male and female breast cancer.PLoS One2013
23560250The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.Springerplus2013
23093495Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.Mol Pharmacol2013
22918167High proliferation is associated with inferior outcome in male breast cancer patients.Mod Pathol2013
21331623Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer.Breast Cancer Res Treat2012
  • 1 - 50 of 73

Recommended Authors

Hans Kristian Moen Vollan
F Hoffmann-La Roche Ltd
Career Start Year 2010
Number of shared co-authors 5
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 7
Felipe C Geyer
Instituto Do Cancer Do Estado de Sao Paulo
Career Start Year 2009
Number of shared co-authors 4
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 4
Samuel Leung
University of British Columbia
Career Start Year 2007
Number of shared co-authors 8
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 4
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 9
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 5
Caterina Marchi??
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Career Start Year 2005
Number of shared co-authors 5
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 7
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 13
Peter T Simpson
UQ Centre for Clinical Research, The University of Queensland
Career Start Year 2003
Number of shared co-authors 10
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 0
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 10
Maryou B Lambros
The Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 4
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 7
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 7
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 3
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 17
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 3
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Career Start Year 1995
Number of shared co-authors 13
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 2
David G Huntsman
University of British Columbia
Career Start Year 1994
Number of shared co-authors 10
Rosemary L Balleine
Westmead Institute for Medical Research, The University of Sydney
Career Start Year 1993
Number of shared co-authors 11
Maria Aparecida Azevedo Koike Folgueira
Center for Translational Oncology, Cancer Institute of the State of Sao Paulo - ICESP
Career Start Year 1993
Number of shared co-authors 0
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 26
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 8
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 33
Vessela N Kristensen
Faculty of Clinical Medicine, University of Oslo
Career Start Year 1983
Number of shared co-authors 17
Irene L Andrulis
University of Toronto
Career Start Year 1977
Number of shared co-authors 20

Collaborators

Cecilia Nilsson
Hospital of Vastmanland Vasteras
Co-authored papers 10
Barbro Linderholm
Sahlgrenska University Hospital
Co-authored papers 4
Karin Jirstr??m
Lund University
Co-authored papers 4
Carolien H M van Deurzen
Erasmus MC Cancer Institute
Co-authored papers 3
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Co-authored papers 3
Kim Benstead
Gloucestershire Hospitals NHS Foundation Trust
Co-authored papers 2
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 2
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 2
Alison M Dunning
Co-authored papers 2
Lavinia P Middleton
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Stefan Aebi
University of Bern
Co-authored papers 2
A E van Leeuwen-Stok
Free University Hospital
Co-authored papers 2
Aleksandra Peric
Co-authored papers 2
Douglas F Easton
University of Cambridge
Co-authored papers 2
Yidong Chen
Zhujiang Hospital, Southern Medical University
Co-authored papers 2
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 2
Jane Bayani
Ontario Institute for Cancer Research
Co-authored papers 2
John M S Bartlett
University of Edinburgh
Co-authored papers 2
Larissa A Korde
Clinical Investigations Branch, National Cancer Institute
Co-authored papers 2
Oliver B??gler
American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University
Co-authored papers 2
Lissandra Dal Lago
Institut Jules Bordet
Co-authored papers 2
Isabel T Rubio
Clinica Universidad de Navarra, Cancer Center Universidad de Navarra
Co-authored papers 2
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Co-authored papers 2
Peggy L Porter
Fred Hutchinson Cancer Research Center
Co-authored papers 2
Sharon H Giordano
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Domenico Palli
Co-authored papers 2
Coralie Poncet
Co-authored papers 2
Christi J van Asperen
Leiden University Medical Center
Co-authored papers 2
Kathryn J Ruddy
Mayo Clinic
Co-authored papers 2
Catherine M Kelly
Mater Misericordiae University Hospital
Co-authored papers 2
Release 1.2